Drug Trial Radar · NCT07524322
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Jul 21, 2026
Primary completion
Apr 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Regor Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.
Conditions
- Breast Cancer
- Ovarian Cancer
- Endometrial Cancer
- PIK3CA Mutation
- HER2- Negative Breast Cancer
- Advanced Breast Cancer
- Unresectable Solid Tumor
- Hormone Receptor Positive Tumor
- Cervical Cancer
Interventions
RGT-490Drug
Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs)Time frame: 4 weeks (1 cycle)
- Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Every cycle (4-week cycles) until study discontinuation, approximately 12 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
START Los Angeles
Los Angeles, California · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Houston
Houston, Texas · Recruiting
NEXT San Antonio
San Antonio, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.